市場調査レポート

商品コード

肝動脈化学塞栓療法（TACE）の世界市場：2030年までの予測

Transarterial Chemoembolization Market Forecast 2030

出版日: 2023年03月03日 | 発行: Market Research Future

| ページ情報: 英文 125 Pages | 納期: お問合せ

価格

PDF (Single User License)

USD 4,950 777,843円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。

PDF (Multi User License)

USD 5,950 934,983円

レポートPDFを同一企業内の最大10名がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。

PDF (Enterprise License)

USD 7,250 1,139,265円

レポートPDFを同一企業内のすべての方がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の肝動脈化学塞栓療法（TACE）の市場規模は、2030年までの調査期間中に4.90%のCAGRで成長し、156億1,000万米ドルに達すると予測されています。肝細胞がんに関する情報の拡充や早期発見、医療費の増加は、市場の成長を促進しています。

当レポートでは、世界の肝動脈化学塞栓療法（TACE）市場について調査分析し、市場力学、市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

概要
化学療法剤
- ドキソルビシン
- シスプラチン
- マイトマイシン
- その他
放射線治療薬
- イットリウム-90マイクロスフィア
- ヨウ素-131リピオドール
- レニウム-188リピオドール
- リン-32ガラスマイクロスフィア
- ホルミウム-166キトサン錯体
- その他
薬物溶出粒子
- ポリビニルアルコールマイクロスフィア
- ポリマーマイクロスフィア
- その他

第9章世界の肝動脈化学塞栓療法（TACE）市場：エンドユーザー別

概要
病院とクリニック
がん研究センター
その他

第10章世界の肝動脈化学塞栓療法（TACE）市場：地域別

概要
南北アメリカ
- 北米
- ラテンアメリカ
欧州
- 西欧
- 東欧
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域
中東およびアフリカ
- 中東
- アフリカ

第11章企業情勢

概要
競合分析

第12章企業プロファイル

ADVAXIS INC.
BAXTER
BELLICUM PHARMACEUTICALS, INC.
BOSTON SCIENTIFIC CORPORATION
COOK
HIKMA PHARMACEUTICALS PLC
ISOFOL MEDICAL AB
NIPPON KAYAKU CO., LTD.
NOVARTIS
PFIZER
SIRTEX SIR-SPHERES PTY LTD.
SPECTRUM PHARMACEUTICALS, INC.
その他

第13章付録

参考文献
関連レポート

図表

LIST OF TABLES

TABLE 1 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SYNOPSIS, 2022-2030
TABLE 2 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET ESTIMATES & FORECAST, 2022-2030 (USD MILLION)
TABLE 3 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY REGION, 2022-2030 (USD MILLION)
TABLE 8 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 10 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 11 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 12 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 13 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 14 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 15 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 16 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 17 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 18 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 19 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 20 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 21 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 22 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 23 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 24 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 25 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 26 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 27 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 28 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 29 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 30 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 31 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 32 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 33 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 34 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 35 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET
FIGURE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PROCEDURE TYPE, 2022 (%)
FIGURE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY INDICATION, 2022 (%)
FIGURE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PRODUCT TYPE, 2022 (%)
FIGURE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY END USER, 2022 (%)
FIGURE 8 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2022 (%)
FIGURE 7 AMERICAS: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE BY REGION, 2022 (%)
FIGURE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 10 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2022 (%)
FIGURE 11 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 12 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 13 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 14 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 15 ADVAXIS INC.: KEY FINANCIALS
FIGURE 16 ADVAXIS INC. SEGMENTAL REVENUE
FIGURE 17 ADVAXIS INC.: REGIONAL REVENUE
FIGURE 18 BAXTER: KEY FINANCIALS
FIGURE 19 BAXTER: SEGMENTAL REVENUE
FIGURE 20 BAXTER: REGIONAL REVENUE
FIGURE 21 BELLICUM PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 22 BELLICUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 23 BELLICUM PHARMACEUTICALS, INC.: REGIONAL REVENUE
FIGURE 24 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS
FIGURE 25 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE
FIGURE 26 BOSTON SCIENTIFIC CORPORATION: REGIONAL REVENUE
FIGURE 27 COOK: KEY FINANCIALS
FIGURE 28 COOK: SEGMENTAL REVENUE
FIGURE 29 COOK: REGIONAL REVENUE
FIGURE 30 HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS
FIGURE 31 HIKMA PHARMACEUTICALS PLC: SEGMENTAL REVENUE
FIGURE 32 HIKMA PHARMACEUTICALS PLC: REGIONAL REVENUE
FIGURE 33 ISOFOL MEDICAL AB: KEY FINANCIALS
FIGURE 34 ISOFOL MEDICAL AB: SEGMENTAL REVENUE
FIGURE 35 ISOFOL MEDICAL AB: REGIONAL REVENUE
FIGURE 36 NIPPON KAYAKU CO., LTD.: KEY FINANCIALS
FIGURE 37 NIPPON KAYAKU CO., LTD.: SEGMENTAL REVENUE
FIGURE 38 NIPPON KAYAKU CO., LTD.: REGIONAL REVENUE
FIGURE 39 NOVARTIS: KEY FINANCIALS
FIGURE 40 NOVARTIS: SEGMENTAL REVENUE
FIGURE 41 NOVARTIS: REGIONAL REVENUE
FIGURE 42 PFIZER: KEY FINANCIALS
FIGURE 43 PFIZER: SEGMENTAL REVENUE
FIGURE 44 PFIZER: REGIONAL REVENUE
FIGURE 45 SIRTEX SIR-SPHERES PTY LTD.: KEY FINANCIALS
FIGURE 46 SIRTEX SIR-SPHERES PTY LTD.: SEGMENTAL REVENUE
FIGURE 47 SIRTEX SIR-SPHERES PTY LTD.: REGIONAL REVENUE
FIGURE 48 SPECTRUM PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 49 SPECTRUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 50 SPECTRUM PHARMACEUTICALS, INC.: REGIONAL REVENUE

Product Code: MRFR/HC/7092-HCR

Market Overview

As per the most recent examination report, the transarterial chemoembolization (TACE) market is projected to arrive at USD 15.61 Billion by 2030 at a 4.90% CAGR during the review period. Hepatocellular carcinoma is an essential growth of the liver that grows for the most part because of persistent liver issues and cirrhosis in most cases. The sickness influences north of 500,000 people globally and is the third biggest reason for malignant growth mortality in the globe.

The utilization of transarterial chemoembolization achieves therapy for liver disease. It works on the standard of removing the bloodstream to the growth. When a stock has been cut off, chemotherapy is managed straightforwardly into the growth. Treatment for individuals with transitional-stage hepatocellular carcinoma is controlled intravenously. The customary transarterial chemoembolization market is respected to be the standard gold treatment for HCC in the US. It is additionally conceivable to use microspheres as medication transporters during transarterial chemoembolization, which might limit the degree of chemotherapeutics in the patient's foundational dissemination.

Moreover, the report likewise contains the perfection of elements, division, central participants, regional examination, and other fundamental variables. What's more, a definite examination of the global Transarterial Chemoembolization (TACE) Market estimate for 2025 is likewise remembered for the report. HCC is the fifth most analyzed disease on the planet, and it is the second most prominent reason for malignant growth mortality in guys all around the globe. The high-grade cervical disease is more normal in Asia and Africa.

Segmentation Overview

The market is fragmented based on applications, system type, product type, end-users, and regions. The global Transarterial Chemoembolization (TACE) Market trends are supposed to observe good development during the estimated time frame.

In view of the Application, the market is sectioned into Chemotherapeutic Specialists, Radiotherapeutic Specialists, and Medication eluting Particles. In view of the drive types, the market is fragmented into medical clinics and Facilities and Malignant growth Exploration Focuses.

Regional Analysis

The transarterial chemoembolization (TACE) market is seeing huge development in America due to expanded information on HCC and early recognition. Accordingly, the American Relationship of Liver Illnesses recommends that people in peril for HCC go through hepatic imaging once a half year to screen their condition. The medical services frameworks of Europe are among the best on the planet. Thusly, transarterial chemoembolization (TACE) market is seeing an expansion popular inferable from increment medical care costs.

As the world's most crowded mainland and where hepatocellular carcinoma is turning out to be increasingly normal, Asia-Pacific is home to the quickest developing TACE global market. There have been numerous occurrences in Asian countries.

Major Players

Major Players in the transarterial Chemoembolization (TACE) Market are Baxter (US), Novartis (Switzerland), Bellicum Pharmaceuticals, Inc. (US), Hikma Pharmaceuticals PLC (UK), Cook (US), Isofol Medical AB (Sweden), Nippon Kayaku Co., Ltd. (Japan), Pfizer (US), Sirtex SIR-Spheres Pty Ltd. (Australia), Boston Scientific Corporation (US), Spectrum Pharmaceuticals, Inc. (US), Advaxis Inc. (US), and Jiangsu Hengrui Medicine Co., Ltd. (China).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. DEFINITION
2.2. SCOPE OF THE STUDY
- 2.2.1. RESEARCH OBJECTIVE
- 2.2.2. ASSUMPTIONS
- 2.2.3. LIMITATIONS

3. RESEARCH METHODOLOGY

3.1. OVERVIEW
3.2. PRIMARY RESEARCH
3.3. SECONDARY RESEARCH
3.4. MARKET SIZE ESTIMATION

4. MARKET DYNAMICS

4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES